Literature DB >> 25041772

Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.

E Jolliffe1, K Romeril.   

Abstract

Autoimmune manifestations are a common occurrence with chronic lymphocytic leukaemia (CLL). We describe a case of CLL-associated immune thrombocytopenia (ITP) that had a loss of response to standard treatment for ITP. The thrombopoeitin receptor agonist, eltrombopag, was successfully used preoperatively to increase the platelet count to a safer level, in this instance to facilitate laparoscopic splenectomy.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.

Entities:  

Keywords:  chronic lymphocytic leukaemia; eltrombopag; immune thrombocytopenia; thrombopoeitin receptor agonist

Mesh:

Substances:

Year:  2014        PMID: 25041772     DOI: 10.1111/imj.12468

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  3 in total

Review 1.  A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Authors:  Mazie Tsang; Sameer A Parikh
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

2.  Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case.

Authors:  Cristina Santoro; Paola Volpicelli; Erminia Baldacci; Grazia Ferrara; Alice Di Rocco; Antonietta Ferretti; Marika Porrazzo; Maria Gabriella Mazzucconi
Journal:  Clin Case Rep       Date:  2017-07-13

3.  Successful Long-Term Use of Eltrombopag in a Patient with Refractory Severe Thrombocytopenia Associated with Chronic Lymphocytic Leukemia That Allowed Oral Anticoagulant Treatment for Severe Cardiomyopathy.

Authors:  Juárez Salcedo Luis Miguel; Gil-Fernández Juan José
Journal:  Case Rep Hematol       Date:  2017-04-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.